Clinical Trial

A Study Evaluating NPT 2042 Versus Placebo in Subjects Aged 16-75 Years With Genetic Generalized Epilepsy (GGE) and Absence Seizures

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will compare the effect of NPT 2042 and placebo in subjects with GGE on the frequency and duration of electroencephalographic absence seizures, separated by a 14-day washout period. The study will be a single-center, double-blind, crossover study with subjects receiving either NPT 2042 BID orally or matching placebo BID in each of two treatment periods. Two doses of NPT 2042 will be evaluated.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-07; most recent amendment 2026-05-27.
Status change: Not Yet Recruiting → Recruiting 2025-03-11
Trial Details
NCT Number NCT06769659
Lead Sponsor NeuroPro Therapeutics, Inc.
Conditions Epilepsy, Generalized, Epilepsy, Absence
Enrollment 12 participants
Start Date 2025-03-11
Primary Completion 2026-08-30 (estimated)
Study Completion 2026-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-29